RZLT Rezolute, Inc.

QT23

Latest market price

3.95

-0.17-4.13%

Overview Short InterestFilings

RZLTQT23Rezolute, Inc.·NASDAQ

Overview Short InterestFilings

3.95-4.13%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

TRAX-0.33%$45.08 NVAX-3.72%$10.08 NUVB-0.21%$4.76 KLRA-4.10%$12.86 REPL+1.27%$17.61 STOK-0.23%$26.29 QURE-1.86%$24.83 NTLA-5.74%$12.47

Snapshot

Index	—	P/E	—	EPS (ttm)	-0.76	Insider Own	—	Shs Outstand	96.72M	Perf Week	2.33%

Market Cap	382.05M	Forward P/E	—	EPS next Y	-0.52	Insider Trans	0.00%	Shs Float	60.77M	Perf Month	-2.95%

Enterprise Value	274.05M	PEG	—	EPS next Q	-0.18			Short Float	31.54%	Perf Quarter	-19.55%

Income	-77.00M	P/S	—	EPS this Y	—			Short Ratio	12.76	Perf Half Y	19.70%

Sales	0.00	P/B	3.78	EPS next Y	—	ROA	-68.75%	Short Interest	19.17M	Perf YTD	67.37%

Book/sh	1.04	P/C	3.54	EPS next 5Y	—	ROE	-62.99%	52W High	11.46 -65.53%	Perf Year	-58.55%

Cash/sh	1.12	P/FCF	—	EPS past 3/5Y	—	ROIC	-81.27%	52W Low	1.07 269.16%	Perf 3Y	283.50%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	0.00%	Volatility	6.33% 7.88%	Perf 5Y	-39.23%

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	0.00%	ATR (14)	0.29	Perf 10Y	-93.52%

Dividend Ex-Date	—	Quick Ratio	9.44	Sales Y/Y TTM	—	Profit Margin	0.00%	RSI (14)	45.85	Recom	2.00

Dividend Gr. 3/5Y	—	Current Ratio	9.44	EPS Q/Q	23.08%	SMA20	-4.55%	Beta	0.61	Target Price	9.17

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	—	SMA50	-7.14%	Rel Volume	0.51	Prev Close	4.12

Employees	58	LT Debt/Eq	0.00	Earnings	Nov 05	SMA200	1.59%	Avg Volume	1.52M	Price	3.95

IPO Date	Jan 14, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	-35.27% —	Net Debt/EBITDA	—	Volume	779,005	Change	-4.13%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-06-26	Reiterated	Lake Street	Buy	$9.00 → $12
Oct-06-26	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Sep-30-26	Initiated	Lake Street	Buy	$9.00
Sep-29-26	Upgrade	Craig-Hallum	Hold → Buy	$2.00 → $7.00
Sep-25-26	Reiterated	HC Wainwright & Co.	Buy	$5.00 → $10
Jun-03-26	Upgrade	Citizens	Market Perform → Market Outperform
Jun-03-26	Reiterated	Wedbush	Outperform	$2.00 → $6.00
Jun-02-26	Reiterated	BTIG	Buy	$5.00 → $6.00
May-14-26	Reiterated	Maxim Group	Buy	$4.00 → $10
Mar-25-26	Upgrade	Wedbush	Neutral → Outperform

Latest News· Times ET

Oct-27-26

Oct-27-2604:19AM

Rezolute (NASDAQ:RZLT) Stock Price Crosses Below 200-Day Moving Average – What’s Next?defenseworld.net

Oct-14-26

Oct-14-2604:05PM

Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinismglobenewswire.com

Oct-08-26

Oct-08-2604:29AM

Rezolute, Inc. (NASDAQ:RZLT) Stock Now Rated “Moderate Buy” by Sell-Side Analystsdefenseworld.net

Oct-07-26

Oct-07-2604:39AM

This NetApp Analyst Turns Bullish; Here Are Top 5 Upgrades For WednesdayBenzinga

Oct-05-26

Oct-05-2605:00PM

These stocks are moving in today's after hours sessionChartMill

11:01AM

Rezolute (NASDAQ:RZLT) Stock Sees Unusually High Call Option Buyingdefenseworld.net

07:00AM

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinismglobenewswire.com

Sep-28-26

Sep-28-2602:22AM

5 Stock Picks Last Week From Wall Street's Most Accurate AnalystsBenzinga

Sep-24-26

Sep-24-2604:05PM

Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Updateglobenewswire.com

Sep-16-26

Sep-16-2601:29AM

Rezolute, Inc. (NASDAQ:RZLT) Receives $9.38 Average Price Target from Analystsdefenseworld.net

Sep-09-26

Sep-09-2607:00AM

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinismglobenewswire.com

03:06AM

Rezolute Said FDA Is Still Reviewing Ersodetug Submission In Congenital Hyperinsulinism; The Company Continues To Await Feedback And Reserves The Ability To Request Formal Meeting Under Regulatory TimelineBenzinga

Sep-02-26

Sep-02-2607:30AM

Rezolute to Participate in Upcoming Investor Conferencesglobenewswire.com

Aug-25-26

Aug-25-2603:52AM

Rezolute, Inc. $RZLT Shares Sold by Bank of America Corp DEdefenseworld.net

Aug-21-26

Aug-21-2606:18AM

MARA Holdings, Coinbase Global, Ternium And Other Big Stocks Moving Higher On FridayBenzinga

Company

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2026 6/30/2026	FY 2025 6/30/2025	FY 2024 6/30/2024	FY 2023 6/30/2023	FY 2022 6/30/2022	FY 2021 6/30/2021	FY 2020 6/30/2020	FY 2019 6/30/2019
Total Revenue	0	0	0	0	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	0	—	—	—	—	—
Gross Profit	0	0	0	0	—	—	—	—	—
Selling, General and Administrative Excl. Other	30	29	18	15	—	—	—	—	—
Research and Development	53	54	62	56	—	—	—	—	—
Other Operating Expense	0	0	0	-1	—	—	—	—	—
Operating Income	-83	-83	-80	-70	—	—	—	—	—
Interest Expense	0	0	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	5	5	5	2	—	—	—	—	—
Net Income Before Taxes	-77	-78	-74	-68	—	—	—	—	—
Income Taxes	0	0	0	0	—	—	—	—	—
Consolidated Net Income	-77	-78	-74	-68	—	—	—	—	—
Net Income From Continuing Operations	-77	-78	-74	-68	—	—	—	—	—
Net Income	-77	-78	-74	-68	—	—	—	—	—
EPS (Recurring)	-0.76	-0.75	-0.98	-1.33	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-0.76	-0.75	-0.98	-1.33	—	—	—	—	—
EPS (Diluted)	-0.76	-0.75	-0.98	-1.33	—	—	—	—	—
EBITDA	-79	-83	-74	-68	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	104	104	76	51	—	—	—	—	—
Market Capitalization	411	541	339	219	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Evans Daron	CFO	Mar 30 '26	Buy	2.85	10,000	28,500	414,462	Mar 31
Hogenhuis Wladimir	Director	Dec 16 '25	Buy	1.69	5,650	9,549	119,675	Dec 17
ROBERTS BRIAN KENNETH	Chief Medical Officer	Dec 16 '25	Buy	1.70	28,000	47,600	308,352	Dec 17
Evans Daron	CFO	Dec 15 '25	Buy	1.77	45,000	79,578	415,900	Dec 15
Elam Nevan C	CEO	Dec 15 '25	Buy	1.59	32,000	50,880	641,119	Dec 15
Karnawat Sunil Ratilal	Chief Commercial Officer	Dec 15 '25	Buy	1.62	12,100	19,599	71,542	Dec 15
ROBERTS BRIAN KENNETH	Chief Medical Officer	Jun 25 '25	Buy	4.38	2,500	10,939	15,500	Jun 26
Evans Daron	CFO	Jun 24 '25	Buy	4.05	5,000	20,250	268,900	Jun 24
Kim Young-Jin	Director	Jun 13 '25	Buy	3.25	1,230,769	3,999,999	8,423,386	Jun 23
KREHER NERISSA	Director	Jun 13 '25	Buy	3.25	3,076	9,997	37,576	Jun 23
Hogenhuis Wladimir	Director	Mar 31 '25	Buy	2.92	6,758	19,733	84,025	Apr 01
Elam Nevan C	CEO	Mar 27 '25	Buy	2.85	12,302	34,999	224,119	Mar 31
Evans Daron	CFO	Mar 26 '25	Buy	2.88	20,000	57,700	237,900	Mar 28
Hogenhuis Wladimir	Director	Feb 18 '25	Buy	4.70	10,000	47,000	77,267	Feb 20
Kim Young-Jin	Director	Jun 25 '24	Buy	4.00	1,250,000	5,000,000	7,192,617	Feb 19

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.